Skip to main content
. 2022 Mar 16;79(17):1717–1756. doi: 10.1016/j.jacc.2022.02.003

Figure 4.

Figure 4

Favorable Benefit-to-Risk Ratio for COVID-19 mRNA Vaccination Among Those at Highest Risk for Postvaccination Myocarditis

∗Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET).12,141 COVID-19 = novel coronavirus disease 2019; ICU = intensive care unit, mRNA = messenger RNA.